Eli Lilly blows past quarterly estimates, hikes outlook as Zepbound and Mounjaro sales skyrocket
CNBC1 min read
Read Full Article at CNBC →Ad Slot — In-Article (728x90)
Lilly hiked its full-year sales outlook by $2 billion, and also raised its adjusted profit guidance.
This is a summary. For the full story, read the original article at CNBC.
Original source: CNBC